Pharmacopedia - Recent changes [en]

MediaWiki:Sidebar

MDElliottMD — Thu, 28 May 2026 10:24:01 GMT

Sidebar: add Administer Assessments after My Life Story (My account parity with PCP nav rail)

← Older revision		Revision as of 10:24, 28 May 2026
(One intermediate revision by the same user not shown)
Line 5:		Line 5:
	** Special:MyProfile#pcp-assessments\|My Assessments		** Special:MyProfile#pcp-assessments\|My Assessments
	** Special:MyLifeStory\|My Life Story		** Special:MyLifeStory\|My Life Story
			** Special:AdministerAssessments\|Administer Assessments
	** Category_index\|Med Classes		** Category_index\|Med Classes
	** Special:Problems\|Problems		** Special:Problems\|Problems
	** recentchanges-url\|recentchanges		** recentchanges-url\|recentchanges
			** Special:FeatureRequests\|Feature requests
	* SEARCH		* SEARCH
	* TOOLBOX		* TOOLBOX
	* LANGUAGES		* LANGUAGES

About:Privacy

MDElliottMD — Thu, 28 May 2026 08:11:14 GMT

Privacy: expand OAuth-consumer list (PCPapp + PubSci + Oyami); Trykl noted as future

← Older revision		Revision as of 08:11, 28 May 2026
Line 5:		Line 5:
	Pharmacopedia (PCP) is operated by Mark Elliott, MD, who is the data controller for everything you do on the wiki: your account, your edits, your profile, your assessments, your observations, and any other content you store against your account. There is no company or entity behind the site; Mark is responsible for it personally.		Pharmacopedia (PCP) is operated by Mark Elliott, MD, who is the data controller for everything you do on the wiki: your account, your edits, your profile, your assessments, your observations, and any other content you store against your account. There is no company or entity behind the site; Mark is responsible for it personally.

	PCP.wiki also acts as an identity provider: other apps or sites can let you sign in using your PCP account through OAuth (the same pattern as "Sign in with Google"). When you authorize one of those consumer apps, it can read the parts of your PCP data that you grant it. Each consumer app is an independent data controller for its own platform data and for what it does with the PCP data it pulls. ~~The currently~~ public ~~consumer is~~ PCPapp, the official Pharmacopedia mobile app. You can review and revoke consumer authorizations at [[Special:OAuthManageMyGrants]].		PCP.wiki also acts as an identity provider: other apps or sites can let you sign in using your PCP account through OAuth (the same pattern as "Sign in with Google"). When you authorize one of those consumer apps, it can read the parts of your PCP data that you grant it. Each consumer app is an independent data controller for its own platform data and for what it does with the PCP data it pulls. Current public consumers are PCPapp (the official Pharmacopedia mobile app), PubSci (an open peer-review wiki at pubsci.io), and Oyami (a periodic-conversation platform at oyami.org). Trykl will be added when it launches publicly. You can review and revoke consumer authorizations at [[Special:OAuthManageMyGrants]].

	For PCP-side access, correction, or deletion requests, contact the address at the bottom of this page.		For PCP-side access, correction, or deletion requests, contact the address at the bottom of this page.

About:Pharmacopedia.ext

MDElliottMD — Thu, 28 May 2026 07:19:22 GMT

0.9.8.7 close-out: hold-to-expand + vote removal + editor tools (boss-claude)

@@ Line 6: / Line 6: @@
 * Structured medicine pages via the <code><nowiki>{{MedTemplate}}</nowiki></code> template
-* Per-user rating on effects, problems, titration strategies, anecdotes, and drug-drug interactions (continuous 0–100 sliders, ±100 valence; no 0–5 likert anywhere)
+* Per-user rating on effects, problems, titration strategies, anecdotes, and drug-drug interactions (continuous 0–100 sliders, ±100 valence; no 0–5 likert anywhere); ratings use a hold-to-expand star widget (300 ms press, spring animation, drag-commit with pixel-travel + value-delta guards); voters can remove their own committed rating
 * Binary AND choice/multi voting on arbitrary content (<code>type="single"</code> / <code>type="multi"</code> with 2-5 options, results-visibility policy per element)
 * Two-perspective data capture (personal vs. provider) wherever clinically meaningful
@@ Line 39: / Line 39: @@
 * '''Backend (PHP):''' <code>includes/</code>, one class per parser tag, store, special page, or API module. Auto-loaded under <code>MediaWiki\Extension\Pharmacopedia\</code>. Assessment classes under <code>includes/Assessments/</code>. API modules under <code>includes/Api/</code>.
 * '''Frontend (JS / CSS):''' multiple ResourceModules per surface area:
-** <code>ext.pharmacopedia</code>: main IIFE (chip-picker, dx autocomplete, BFI-10 compute, vote logic for both binary and choice/multi)
+** <code>ext.pharmacopedia</code>: main IIFE (chip-picker, dx autocomplete, BFI-10 compute, vote logic for both binary and choice/multi, hold-to-expand star rating model with spring animation and drag-commit, vote removal)
 ** <code>ext.pharmacopedia.styles</code>: base extension stylesheet (self-hosted Geist / Newsreader / Source Serif fonts, core component styling)
 ** <code>ext.pharmacopedia.blocksave</code>: debounced autosave per block (race-safe)
@@ Line 49: / Line 49: @@
 ** <code>ext.pharmacopedia.perspective</code>: observer-perspective form enhancement (slider readout, progress, consent/delete confirm)
 ** <code>ext.pharmacopedia.administer</code>: the administer-to-others surfaces (take-flow slider readout + "Not sure" toggling, owner-hub styling)
 ** <code>ext.pharmacopedia.observation</code>: quick-add observation textarea + live preview
 ** <code>ext.pharmacopedia.refupgrade</code>: bulk linker for free-text → structured refs
@@ Line 377: / Line 378: @@
 Server-side aggregates: <code>n</code>, mean of the rating field, and (for interactions) <code>severe = (vmean ≤ −83.0)</code> (rescaled from the original ±3-scale −2.5). Aggregates are recomputed and returned by every report-submit API call so the row re-renders in place without a page reload.
 == Effect bucketing ==
@@ Line 752: / Line 771: @@
 Scroll position is preserved across the rare reloads (delete operations on diagnoses / medicines / experience reports, and the auto-reload after a new diagnosis or medicine is added) via <code>sessionStorage</code> (the <code>ext.pharmacopedia.bounceback</code> module).
 == Special pages ==

Paper:Test define widget

MDElliottMD — Thu, 28 May 2026 01:38:19 GMT

OOPS

← Older revision		Revision as of 01:38, 28 May 2026
Line 1:		Line 1:
	~~== Introduction ==~~

	~~The study of <define term="pharmacokinetics">pharmacokinetics</define> examines how~~
	~~medicines behave in the body. <define term="bioavailability" style="margin">Bioavailability</define>~~
	~~describes the fraction of a dose that reaches systemic circulation.~~
	~~<define term="half_life" style="glass">Half-life</define> governs dosing frequency.~~

	~~Select any 1-4 words in this sentence to test the skin text-selection panel.~~

Paper:Test define widget

MDElliottMD — Thu, 28 May 2026 01:35:38 GMT

Created page with "== Introduction == The study of <define term="pharmacokinetics">pharmacokinetics</define> examines how medicines behave in the body. <define term="bioavailability" style="margin">Bioavailability</define> describes the fraction of a dose that reaches systemic circulation. <define term="half_life" style="glass">Half-life</define> governs dosing frequency. Select any 1-4 words in this sentence to test the skin text-selection panel."

New page

== Introduction ==

The study of <define term="pharmacokinetics">pharmacokinetics</define> examines how
medicines behave in the body. <define term="bioavailability" style="margin">Bioavailability</define>
describes the fraction of a dose that reaches systemic circulation.
<define term="half_life" style="glass">Half-life</define> governs dosing frequency.

Select any 1-4 words in this sentence to test the skin text-selection panel.

Template:DefineEntry

PCP-Bot — Wed, 27 May 2026 23:47:01 GMT

define widget: add DefineEntry template for cross-empire definitions

New page

<noinclude>
'''DefineEntry''' -- structured definition template for the cross-empire define widget.

Usage:

{{DefineEntry
| style = glass
| definition = A brief definition (max 400 chars for glass style).
| field = Neuroscience
| see_also = action-potential, ion-channel
| source = Kandel et al., Principles of Neural Science, 6th ed.
}}

style: one of whisper (max 200 chars, definition only), margin (max 300 chars, source optional), glass (max 400 chars, all fields).
definition: required. Plain text, no wikimarkup.
field: optional. Subject domain.
see_also: optional. Comma-separated slugs (hyphens for spaces, lowercase).
source: optional. Citation string, plain text.

Definitions served at: https://pharmacopedia.wiki/rest.php/pharmacopedia/v1/define/{slug}
</noinclude>

MediaWiki:Welcomecreation-msg

PCP-Bot — Wed, 27 May 2026 21:12:23 GMT

email widget: add optional e-mail bullet to welcome page

← Older revision		Revision as of 21:12, 27 May 2026
Line 8:		Line 8:
	* '''THIRD:''' You can [[Experience_Sharing\|share your experiences]] almost everywhere on the site, but the most efficient and thorough way is through [[Special:MyProfile]], where you can build a comprehensive and (selectively and extremely) private story of your life with essentially arbitrary detail.		* '''THIRD:''' You can [[Experience_Sharing\|share your experiences]] almost everywhere on the site, but the most efficient and thorough way is through [[Special:MyProfile]], where you can build a comprehensive and (selectively and extremely) private story of your life with essentially arbitrary detail.
	* '''FOURTH:''' The assessment system in Pharmacopedia is rather extensive. Check it out at [[Special:MyProfile]] or find it in the left sidebar. If you're lost, you'll find yourself in that sidebar.		* '''FOURTH:''' The assessment system in Pharmacopedia is rather extensive. Check it out at [[Special:MyProfile]] or find it in the left sidebar. If you're lost, you'll find yourself in that sidebar.
			* '''FIFTH:''' <span class="pcp-email-trigger">add (OPTIONAL) e-mail</span> for password recovery and account access if you ever lose your TOTP device.

MediaWiki:Common.js

MDElliottMD — Wed, 27 May 2026 20:14:01 GMT

← Older revision		Revision as of 20:14, 27 May 2026
Line 1:		Line 1:
	~~<span class="~~pcp-new-tab~~">[[~~{~~{{1}}}\|{{{2\|{{{1}}}}}~~}~~]]</span>~~		document.querySelectorAll( '.pcp-new-tab a' ).forEach( function ( a ) {
			a.target = '_blank';
			a.rel = 'noopener noreferrer';
			} );

MediaWiki:Welcomecreation-msg

MDElliottMD — Wed, 27 May 2026 20:11:07 GMT

made 2FA open in new tab to not lose the welcome page

← Older revision		Revision as of 20:11, 27 May 2026
Line 4:		Line 4:
	A few things to know:		A few things to know:

	* '''FIRST:''' Two-factor authentication (TOTP) is required to contribute to the hive mind. Set it up ASAP [[Special:OATHManage\|here]].		* '''FIRST:''' Two-factor authentication (TOTP) is required to contribute to the hive mind. Set it up ASAP {{NewTab\|Special:OATHManage\|here}}.
	* '''SECOND:''' If you're a licensed healthcare provider, you can apply for verified provider status [[Special:VerifyProvider\|here]] — this lets you contribute observations from your clinical practice on medicine pages.		* '''SECOND:''' If you're a licensed healthcare provider, you can apply for verified provider status [[Special:VerifyProvider\|here]] — this lets you contribute observations from your clinical practice on medicine pages.
	* '''THIRD:''' You can [[Experience_Sharing\|share your experiences]] almost everywhere on the site, but the most efficient and thorough way is through [[Special:MyProfile]], where you can build a comprehensive and (selectively and extremely) private story of your life with essentially arbitrary detail.		* '''THIRD:''' You can [[Experience_Sharing\|share your experiences]] almost everywhere on the site, but the most efficient and thorough way is through [[Special:MyProfile]], where you can build a comprehensive and (selectively and extremely) private story of your life with essentially arbitrary detail.
	* '''FOURTH:''' The assessment system in Pharmacopedia is rather extensive. Check it out at [[Special:MyProfile]] or find it in the left sidebar. If you're lost, you'll find yourself in that sidebar.		* '''FOURTH:''' The assessment system in Pharmacopedia is rather extensive. Check it out at [[Special:MyProfile]] or find it in the left sidebar. If you're lost, you'll find yourself in that sidebar.

MediaWiki:Common.js

MDElliottMD — Wed, 27 May 2026 20:10:17 GMT

Open in new tab Template

New page

Template:NewTab

MDElliottMD — Wed, 27 May 2026 20:07:29 GMT

Adding template for open in new tab across the platform.

New page

User:RealityTesting

RealityTesting — Wed, 27 May 2026 19:44:54 GMT

User account RealityTesting was created

About:Pharmacopedia.ext

MDElliottMD — Wed, 27 May 2026 11:07:05 GMT

0.9.8.7 Security section: correct live TLS config (HIGH:!aNULL, TLS1.0/1.1 allowed), fix LocalSettings.php owner (root:www-data), AbuseFilter 2/2 enabled, OATHAuth 5 recovery codes, HSTS preload pending

← Older revision		Revision as of 11:07, 27 May 2026
Line 68:		Line 68:
	TLS terminates at Apache 2 (mod_ssl) on the same host as the application. No CDN, no reverse proxy, no load balancer is in front. Certificate is a Let's Encrypt ECDSA leaf, renewed by <code>certbot.timer</code> (fires twice daily, renews when within 30 days of expiry). Private key on disk is mode 600 root:root in <code>/etc/letsencrypt/archive/pharmacopedia.wiki/</code>.		TLS terminates at Apache 2 (mod_ssl) on the same host as the application. No CDN, no reverse proxy, no load balancer is in front. Certificate is a Let's Encrypt ECDSA leaf, renewed by <code>certbot.timer</code> (fires twice daily, renews when within 30 days of expiry). Private key on disk is mode 600 root:root in <code>/etc/letsencrypt/archive/pharmacopedia.wiki/</code>.

	Apache TLS config (from <code>/etc/letsencrypt/options-ssl-apache.conf</code>~~, loaded by every Pharmacopedia vhost~~):		Apache TLS config (live from <code>/etc/letsencrypt/options-ssl-apache.conf</code> + <code>/etc/apache2/mods-enabled/ssl.conf</code>):

	SSLProtocol all ~~-SSLv2~~ -SSLv3 ~~-TLSv1 -TLSv1.1~~		SSLProtocol all -SSLv3
	SSLCipherSuite ~~ECDHE-ECDSA-AES128-GCM-SHA256~~:~~ECDHE-RSA-AES128-GCM-SHA256:~~		SSLCipherSuite HIGH:!aNULL
	~~ECDHE-ECDSA-AES256-GCM-SHA384:ECDHE-RSA-AES256-GCM-SHA384:~~
	~~ECDHE-ECDSA-CHACHA20-POLY1305:ECDHE-RSA-CHACHA20-POLY1305:~~
	~~DHE-RSA-AES128-GCM-SHA256:DHE-RSA-AES256-GCM-SHA384~~
	~~SSLHonorCipherOrder off~~
	SSLSessionTickets off		SSLSessionTickets off

	Effective ~~enabled~~: TLS 1.~~2 + TLS~~ 1.3 ~~only~~. ~~TLS 1~~.0 / 1.1 ~~refused~~. <code>SSLSessionTickets off</code> preserves forward secrecy across server restarts.		Effective TLS range: TLS 1.0 through 1.3 (SSLv3 explicitly refused). The cipher suite shorthand <code>HIGH:!aNULL</code> covers all ECDHE + DHE forward-secrecy ciphers but does not exclude TLSv1.0 or TLSv1.1 at the protocol layer. Hardening to an explicit modern list and <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued; see ''Honest limitations'' below. <code>SSLSessionTickets off</code> preserves forward secrecy across server restarts.

	HSTS:		HSTS:
Line 84:		Line 80:
	Strict-Transport-Security: max-age=63072000; includeSubDomains; preload		Strict-Transport-Security: max-age=63072000; includeSubDomains; preload

	Two years, subdomains included, preload-ready.		Two years, subdomains included, preload-ready. The <code>preload</code> directive is present in the header; submission to the Chromium HSTS preload list is pending.

	=== HTTP security headers ===		=== HTTP security headers ===
Line 150:		Line 146:
	The high-trust paths and their modes (no values published):		The high-trust paths and their modes (no values published):

	/var/www/mediawiki/LocalSettings.php 640 ~~www-data~~:www-data		/var/www/mediawiki/LocalSettings.php 640 root:www-data
	contains: $wgSecretKey, $wgUpgradeKey, $wgDBpassword,		contains: $wgSecretKey, $wgUpgradeKey, $wgDBpassword,
	$wgTurnstileSecretKey, $wgSMTP['password'],		$wgTurnstileSecretKey, $wgSMTP['password'],
Line 181:		Line 177:
	MediaWiki passwords are stored as PBKDF2 hashes (MW core default). Verified across every <code>user_password</code> row: HMAC-SHA-512 inner hash, 30,000 iterations, 64-byte derived key, 16-byte random salt per user. The <code>$wgPasswordConfig</code> default is unmodified; bcrypt is available in MW core but not enabled.		MediaWiki passwords are stored as PBKDF2 hashes (MW core default). Verified across every <code>user_password</code> row: HMAC-SHA-512 inner hash, 30,000 iterations, 64-byte derived key, 16-byte random salt per user. The <code>$wgPasswordConfig</code> default is unmodified; bcrypt is available in MW core but not enabled.

	Two-factor authentication via the OATHAuth extension. Default module is TOTP per RFC 6238: HMAC-SHA-1 inner, 6 digits, 30-second time-step, 80-bit shared secret. ~~Ten~~ recovery codes per user, each a random ~~10-character~~ string, hashed at rest, consumed on use. WebAuthn / FIDO2 (passkey) is available in the same extension and is the operator's first-choice path.		Two-factor authentication via the OATHAuth extension. Default module is TOTP per RFC 6238: HMAC-SHA-1 inner, 6 digits, 30-second time-step, 80-bit shared secret. Five recovery codes per user, each a random string, hashed at rest, consumed on use. WebAuthn / FIDO2 (passkey) is available in the same extension and is the operator's first-choice path.

	==== AdminCrypto ====		==== AdminCrypto ====
Line 234:		Line 230:

	* Cloudflare Turnstile gates account creation, repeated failed logins, URL-bearing edits, and email-sending. Editors are not challenged on normal edits (a deliberate friction trade-off).		* Cloudflare Turnstile gates account creation, repeated failed logins, URL-bearing edits, and email-sending. Editors are not challenged on normal edits (a deliberate friction trade-off).
	* The AbuseFilter extension is ~~installed and configured; the~~ active-rule set is small ~~today and~~ the lane will grow as live-fire patterns emerge.		* The AbuseFilter extension is loaded with 2 rules, both enabled as of 0.9.8.7. Rule 1: spam-keyword block (block + disallow). Rule 2: new-account edit throttle (throttle). The active rule set is small; the lane will grow as live-fire patterns emerge.
	* Every file or image upload is scanned by ClamAV before the file moves into the persistent store. The scanner is run via <code>clamdscan</code> (persistent daemon, fast) with a fallback to <code>clamscan</code>. The gate is fail-closed: exit 0 = clean (proceed), exit 1 = infected (reject + unlink), any other exit = error (reject + unlink). A scanner crash never becomes a pass.		* Every file or image upload is scanned by ClamAV before the file moves into the persistent store. The scanner is run via <code>clamdscan</code> (persistent daemon, fast) with a fallback to <code>clamscan</code>. The gate is fail-closed: exit 0 = clean (proceed), exit 1 = infected (reject + unlink), any other exit = error (reject + unlink). A scanner crash never becomes a pass.
	* fail2ban (see ''SSH + host'' above) bans abusive IPs at the network layer.		* fail2ban (see ''SSH + host'' above) bans abusive IPs at the network layer.
Line 247:		Line 243:
	* '''No CDN, no DDoS layer.''' One VM, three open ports, UFW + fail2ban. Hostile traffic can take the site down; it cannot exfiltrate.		* '''No CDN, no DDoS layer.''' One VM, three open ports, UFW + fail2ban. Hostile traffic can take the site down; it cannot exfiltrate.
	* '''Some application-layer key rotation is "never" by design.''' The voter-hash secret and the AdminCrypto Mode B master key cannot rotate without breaking either anonymity or existing wrappings respectively. Loss of either key has the obvious one-time consequence; trading that off against the alternative (re-encrypt every historical record) was the deliberate choice.		* '''Some application-layer key rotation is "never" by design.''' The voter-hash secret and the AdminCrypto Mode B master key cannot rotate without breaking either anonymity or existing wrappings respectively. Loss of either key has the obvious one-time consequence; trading that off against the alternative (re-encrypt every historical record) was the deliberate choice.
	* '''~~Two enabled AbuseFilter rules~~.''' The ~~pipeline~~ is ~~in place;~~ the ~~rule set is small~~. ~~Honest signal: this~~ is ~~plumbing for future use, not active filtering today~~.		* '''TLS allows TLSv1.0 and TLSv1.1.''' The live Apache literal is <code>SSLProtocol all -SSLv3</code>, which does not exclude older TLS protocol versions at the protocol layer. Hardening to an explicit modern cipher list with <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued.
	* '''Perspective-invite tokens are half-migrated to hashed storage.''' 0.9.8.7 added the <code>pvi_token_hash</code> column, backfilled it, and switched the lookup to hash-first; the cleartext <code>pvi_token</code> column is still present so the dual-write fallback works during the deploy edge. 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable invite tokens. Severity in the interim: an attacker with DB read can still submit a perspective under a planted invite identity; not access to medical data.		* '''Perspective-invite tokens are half-migrated to hashed storage.''' 0.9.8.7 added the <code>pvi_token_hash</code> column, backfilled it, and switched the lookup to hash-first; the cleartext <code>pvi_token</code> column is still present so the dual-write fallback works during the deploy edge. 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable invite tokens. Severity in the interim: an attacker with DB read can still submit a perspective under a planted invite identity; not access to medical data.

Pharmacopedia:History

MDElliottMD — Wed, 27 May 2026 04:41:18 GMT

historian-claude: Chapter 1 founding and structure, first draft (2026-05-26)

Show changes

Risperidone

MDElliottMD — Wed, 27 May 2026 02:23:05 GMT

home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

← Older revision		Revision as of 02:23, 27 May 2026
Line 16:		Line 16:
	\| pregnancy = Signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.{{citation needed}}		\| pregnancy = Signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.{{citation needed}}
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis<ref name="risperdal-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis<ref name="risperdal-label" />
	\| mechanism = <vote slug="risperidone-mech-claim">'''D2 dopamine receptor antagonist plus 5-HT2A serotonin receptor antagonist''', the classical atypical-neuroleptic signature originally derived from clozapine but with a more dopamine-tilted occupancy profile than olanzapine or quetiapine. The high D2 occupancy at therapeutic doses produces the highest rates of '''hyperprolactinemia''' among second-generation neuroleptics (galactorrhea, amenorrhea, sexual dysfunction, and bone density loss with chronic use), along with dose-dependent extrapyramidal symptoms above ~6 mg/day.</vote> CYP2D6 substrate; CYP2D6 poor metabolizers have higher ~~plasma~~ exposure ~~and may benefit from lower initial dosing~~. ~~CPIC PGx guidance applies~~<ref name="~~cpic~~-~~cyp2d6~~">~~CPIC Guideline~~ for CYP2D6 ~~Genotype~~ and ~~Neuroleptic Dosing~~. ~~https~~:~~//cpicpgx~~.org~~/guidelines/</ref~~>.		\| mechanism = <vote slug="risperidone-mech-claim">'''D2 dopamine receptor antagonist plus 5-HT2A serotonin receptor antagonist''', the classical atypical-neuroleptic signature originally derived from clozapine but with a more dopamine-tilted occupancy profile than olanzapine or quetiapine. The high D2 occupancy at therapeutic doses produces the highest rates of '''hyperprolactinemia''' among second-generation neuroleptics (galactorrhea, amenorrhea, sexual dysfunction, and bone density loss with chronic use), along with dose-dependent extrapyramidal symptoms above ~6 mg/day.</vote> CYP2D6 substrate; CYP2D6 oxidation produces 9-hydroxy-risperidone (paliperidone). CYP2D6 poor metabolizers have higher risperidone exposure, but the active-moiety sum (risperidone plus paliperidone) is relatively preserved across CYP2D6 phenotypes.<ref name="risperdal-label" /> PharmGKB clinical annotations for risperidone-CYP2D6 apply (Level 2A) and the Dutch Pharmacogenetics Working Group (DPWG) has issued CYP2D6 dosing guidance for risperidone.<!-- citation needed: PharmGKB risperidone CYP2D6 annotation Level 2A; DPWG risperidone CYP2D6 dosing guidance. Search: pharmgkb.org risperidone; dpwg risperidone cyp2d6 --> No formal CPIC guideline for neuroleptic CYP2D6 dosing has been published.
	}}		}}

Lamotrigine

MDElliottMD — Wed, 27 May 2026 02:23:04 GMT

home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

← Older revision		Revision as of 02:23, 27 May 2026
Line 16:		Line 16:
	\| pregnancy = '''Among the safest mood stabilizers in pregnancy''' with reassuring monotherapy registry data, in sharp contrast to valproate. Estrogen-containing contraceptives accelerate lamotrigine metabolism, requiring dose adjustments at start and stop of contraception<ref name="lamictal-label" />		\| pregnancy = '''Among the safest mood stabilizers in pregnancy''' with reassuring monotherapy registry data, in sharp contrast to valproate. Estrogen-containing contraceptives accelerate lamotrigine metabolism, requiring dose adjustments at start and stop of contraception<ref name="lamictal-label" />
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the FDA '''Boxed Warning for serious skin reactions''' including Stevens-Johnson syndrome and toxic epidermal necrolysis, with the risk concentrated in the first 2-8 weeks of therapy and elevated by rapid titration<ref name="lamictal-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the FDA '''Boxed Warning for serious skin reactions''' including Stevens-Johnson syndrome and toxic epidermal necrolysis, with the risk concentrated in the first 2-8 weeks of therapy and elevated by rapid titration<ref name="lamictal-label" />
	\| mechanism = <vote slug="lamotrigine-mech-claim">Voltage-gated sodium channel blocker in the inactivated state, reducing high-frequency repetitive neuronal firing and consequently reducing presynaptic glutamate release. The mood-stabilizing mechanism is incompletely characterized but is plausibly the same glutamatergic dampening applied to limbic circuits.</vote> Metabolized predominantly by UGT1A4 glucuronidation (not CYP), which is why '''valproate doubles exposure''' (UGT inhibition) and '''carbamazepine, phenytoin, rifampin halve exposure''' (UGT induction). ~~The~~ HLA-B15:02 ~~allele substantially elevates~~ SJS ~~risk~~ in Asian populations; ~~CPIC and FDA support pre~~-~~treatment~~ HLA-B15:~~02 testing in at~~-~~risk patients~~<ref name="~~cpic-hla~~">~~CPIC Guideline for~~ HLA ~~Genotype~~ and ~~Use of Carbamazepine and Oxcarbazepine, applicable by extension to~~ lamotrigine. ~~https~~:~~//cpicpgx~~.~~org~~/~~guidelines~~/~~guideline~~-for-carbamazepine-~~and-hla-b/<~~/~~ref~~>.		\| mechanism = <vote slug="lamotrigine-mech-claim">Voltage-gated sodium channel blocker in the inactivated state, reducing high-frequency repetitive neuronal firing and consequently reducing presynaptic glutamate release. The mood-stabilizing mechanism is incompletely characterized but is plausibly the same glutamatergic dampening applied to limbic circuits.</vote> Metabolized predominantly by UGT1A4 glucuronidation (not CYP), which is why '''valproate doubles exposure''' (UGT inhibition) and '''carbamazepine, phenytoin, rifampin halve exposure''' (UGT induction). HLA-B15:02 is associated with lamotrigine-induced SJS/TEN in Asian populations, but the association is weaker than for carbamazepine.<ref name="zeng2015lam">Zeng T, Long YS, Min FL, Liao WP. Association of HLA-B1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. Int J Dermatol. 2015;54(4):488-493. PMID 25428396.</ref> In European-ancestry patients, HLA-B38:01 has been identified as a risk allele for lamotrigine-induced SJS.<ref name="kazeem2009lam">Kazeem GR, Cox C, Aponte J, Messenheimer J. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics. 2009;19(9):661-665. PMID 19668019.</ref> The FDA Lamictal label notes HLA-B15:02 as a risk factor for lamotrigine SJS/TEN in patients of Asian ancestry but does not require pre-treatment HLA testing for lamotrigine as the carbamazepine label does.<ref name="lamictal-label" /> CPIC has published a guideline for carbamazepine and oxcarbazepine HLA testing; no formal CPIC guideline for lamotrigine HLA testing has been published.
	}}		}}

Venlafaxine

MDElliottMD — Wed, 27 May 2026 02:23:03 GMT

home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

← Older revision		Revision as of 02:23, 27 May 2026
Line 16:		Line 16:
	\| pregnancy = Observational signal for neonatal adaptation syndrome with late-pregnancy exposure; weigh against the risks of untreated maternal depression.{{citation needed}}		\| pregnancy = Observational signal for neonatal adaptation syndrome with late-pregnancy exposure; weigh against the risks of untreated maternal depression.{{citation needed}}
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="effexor-xr-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="effexor-xr-label" />
	\| mechanism = <vote slug="venlafaxine-mech-claim">Serotonin and norepinephrine reuptake inhibitor with predominantly serotonergic activity at lower doses (37.5-150 mg); the noradrenergic effect adds at higher doses (>150 mg) and the dual-mechanism advantage really emerges then. The active metabolite desvenlafaxine (separately marketed as Pristiq) contributes meaningfully to clinical effect.</vote> '''Severe discontinuation syndrome''' is the marquee adverse-effect feature: venlafaxine's short half-life produces intense flu-like symptoms, dizziness, electric-shock sensations ("brain zaps"), and emotional dysregulation on abrupt discontinuation, worse than most other SNRIs and SSRIs. Slow taper essential. Dose-dependent '''diastolic hypertension''' at higher doses; routine BP monitoring at dose escalation. CYP2D6 substrate; ~~CPIC PGx guidance applies~~<ref name="~~cpic~~-~~snri~~">~~CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, 2023~~. https://~~cpicpgx~~.org/~~guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19~~/</ref>.		\| mechanism = <vote slug="venlafaxine-mech-claim">Serotonin and norepinephrine reuptake inhibitor with predominantly serotonergic activity at lower doses (37.5-150 mg); the noradrenergic effect adds at higher doses (>150 mg) and the dual-mechanism advantage really emerges then. The active metabolite desvenlafaxine (separately marketed as Pristiq) contributes meaningfully to clinical effect.</vote> '''Severe discontinuation syndrome''' is the marquee adverse-effect feature: venlafaxine's short half-life produces intense flu-like symptoms, dizziness, electric-shock sensations ("brain zaps"), and emotional dysregulation on abrupt discontinuation, worse than most other SNRIs and SSRIs. Slow taper essential. Dose-dependent '''diastolic hypertension''' at higher doses; routine BP monitoring at dose escalation. CYP2D6 substrate; CYP2D6 oxidation produces the active metabolite desvenlafaxine. PharmGKB clinical annotations for venlafaxine apply (Level 2A).<ref name="pharmgkb-venlafaxine">PharmGKB: Venlafaxine pharmacogenomics annotations. https://www.pharmgkb.org/chemical/PA451866</ref> No formal CPIC guideline covers venlafaxine; the CPIC SSRI/CYP2D6 guideline (Hicks 2015) covers sertraline, citalopram, escitalopram, fluoxetine, fluvoxamine, and paroxetine and does not extend to SNRIs.
	}}		}}

Methylphenidate

Maintenance script — Wed, 27 May 2026 01:10:09 GMT

parser-claude (pharmacist-claude hat): citation pass + content fills per Mark go 2026-05-26. Adds: history section (Panizzon 1944, Ciba launch, Schedule II 1971, MTA study, Cooper 2011 CV outcomes), Cortese 2018 NMA in intro, FDA warning refs (4), references/> infrastructure, FDA Ritalin label ref on PK, Ritalin IR indication clarification, MPH-TCA interaction revision, anecdote typo fix.

← Older revision		Revision as of 01:10, 27 May 2026
Line 14:		Line 14:
	\| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.		\| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need. A 2018 systematic review and network meta-analysis by Cortese and colleagues identified methylphenidate as first-line pharmacotherapy for ADHD in children and adolescents (based on the balance of efficacy and tolerability), with amphetamines as first-line in adults.<ref name="cortese2018">Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.</ref>
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| history =
			Methylphenidate emerged from a chemistry program at the Swiss pharmaceutical company Ciba AG (later Ciba-Geigy, then Novartis) in the 1940s. Leandro Panizzon, a chemist at Ciba, synthesized the compound in 1944 while searching for a stimulant with a less abrupt and less euphoric profile than amphetamine. Panizzon and his colleagues observed the stimulant effect in animals and ultimately on themselves; the canonical anecdote, widely repeated in pharmacology histories and Ciba/Novartis corporate retrospectives, is that Panizzon's wife Marguerite ("Rita") used the compound as a mild stimulant before tennis matches, which inspired the trade name Ritalin.{{citation needed}}<!-- Candidate: Myers RE. Leandro Panizzon and the discovery of methylphenidate. Or: Ciba-Geigy / Novartis corporate history. The Rita-Panizzon attribution is widely repeated but a primary attribution source should be verified at publish. -->

			Ciba launched methylphenidate as Ritalin in Switzerland in 1954 and in the United States the following year, originally marketed for narcolepsy, chronic fatigue, mild depression, senile behavioral problems, and as an amphetamine-overdose antidote (this last use long since abandoned). Clinical application to childhood behavioral disorders developed gradually through the late 1950s and 1960s; the diagnosis then was "minimal brain dysfunction" or "hyperkinetic reaction of childhood," the precursors to the modern attention-deficit hyperactivity disorder formulation.{{citation needed}}<!-- Candidate: Healy D. The Creation of Psychopharmacology. Harvard University Press, 2002. Or Conrad P. The Discovery of Hyperkinesis: Notes on the Medicalization of Deviant Behavior. Social Problems. 1975;23(1):12–21. -->

			Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.

			The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.{{citation needed}}<!-- Candidate: Swanson JM et al on MTA long-term follow-ups, multiple papers 2007–2019. Verify exact PMID at publish. -->

			Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.
			\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.<ref name="ritalin-label">U.S. Food and Drug Administration. Ritalin (methylphenidate hydrochloride) prescribing information. NDA 010187, Novartis Pharmaceuticals.</ref>
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Line 28:		Line 38:
	* Narcolepsy		* Narcolepsy
	* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder		* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder
	\| dosing = '''Ritalin IR (children ≥6 y~~, adults~~):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.		\| dosing = '''Ritalin IR (FDA-approved for children ≥6 y; adult use is common clinical practice but off-label for IR Ritalin specifically; several ER formulations carry adult ADHD indications):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.
	'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.		'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.
	'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).		'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).
Line 37:		Line 47:
	\| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.		\| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.
	''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.		''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.
	\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (~~FDA warning~~)		\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease.<ref name="fda-mph-cv-2007">U.S. Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. February 21, 2007.</ref><ref name="vetter2008">Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association. Circulation. 2008;117(18):2407–2423.</ref>
	* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)		* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
	* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication		* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
	* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant		* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
	* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children		* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children
	* '''Priapism''', rare but documented; FDA warning, especially in adolescents		* '''Priapism''', rare but documented; FDA warning, especially in adolescents.<ref name="fda-mph-priapism-2013">U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review update of medical drugs used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. December 17, 2013 (priapism class warning).</ref>
	* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia		* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia.<ref name="fda-mph-vasculopathy-2006">U.S. Food and Drug Administration. FDA Drug Safety Communication: peripheral vasculopathy including Raynaud phenomenon associated with stimulants used to treat ADHD. December 2006.</ref>
	* '''Lowered seizure threshold''', caution in epilepsy		* '''Lowered seizure threshold''', caution in epilepsy
	* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity		* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity
	* '''Stereotyped behaviors''', rare at therapeutic doses		* '''Stereotyped behaviors''', rare at therapeutic doses
	* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites		* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites.<ref name="fda-daytrana-leukoderma-2015">U.S. Food and Drug Administration. FDA Drug Safety Communication: Permanent skin color loss (chemical leukoderma) reported with use of Daytrana patch (methylphenidate transdermal system). June 24, 2015.</ref>
	\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated		\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated
	* '''Tricyclic antidepressants''', ~~methylphenidate may elevate~~ TCA ~~plasma~~ levels; ~~additive cardiovascular effects~~		* '''Tricyclic antidepressants''', additive sympathomimetic cardiovascular effects (tachycardia, hypertension). Older case reports suggested possible PK interaction elevating TCA levels; modern reviews do not support a clinically significant PK interaction as methylphenidate does not appreciably inhibit CYP2D6.
	* '''Warfarin / coumarins''', methylphenidate may elevate INR		* '''Warfarin / coumarins''', methylphenidate may elevate INR
	* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels		* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels
Line 79:		Line 89:
	\| anecdotes =		\| anecdotes =
	<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">		<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">
	Rumor has it that can be more ~~effect~~ during luteal phase of ~~menstruation~~. Anyone have experience?		Rumor has it that it can be more effective during the luteal phase of the menstrual cycle. Anyone have experience?
	</anecdote>		</anecdote>
	\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]		\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
	\| references =		\| references = <references/>
	}}		}}

	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

Peppermint

Maintenance script — Tue, 26 May 2026 20:59:08 GMT

Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

← Older revision		Revision as of 20:59, 26 May 2026
Line 136:		Line 136:

	Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.		Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.
			\| references = <references/>
	}}		}}

	~~== References ==~~
	~~<references/>~~

	[[Category:Plants]]		[[Category:Plants]]

Lemon balm

Maintenance script — Tue, 26 May 2026 20:59:07 GMT

Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

← Older revision		Revision as of 20:59, 26 May 2026
Line 135:		Line 135:
	\| traditional_geography =		\| traditional_geography =
	\| anecdotes =		\| anecdotes =
			\| references = <references/>
	}}		}}

	~~== References ==~~
	~~<references/>~~

	[[Category:Plants]]		[[Category:Plants]]

Chinese licorice

Maintenance script — Tue, 26 May 2026 20:59:07 GMT

Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

← Older revision		Revision as of 20:59, 26 May 2026
Line 123:		Line 123:
	\| traditional_geography =		\| traditional_geography =
	\| anecdotes =		\| anecdotes =
			\| references = <references/>
	}}		}}

	~~== References ==~~
	~~<references/>~~

	[[Category:Plants]]		[[Category:Plants]]

Dandelion

Maintenance script — Tue, 26 May 2026 20:55:46 GMT

Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

← Older revision		Revision as of 20:55, 26 May 2026
Line 131:		Line 131:

	MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.		MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.
			\| references = <references/>
	}}		}}

	~~== References ==~~
	~~<references/>~~

	[[Category:Plants]]		[[Category:Plants]]

Lavender

Maintenance script — Tue, 26 May 2026 20:55:20 GMT

Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

← Older revision		Revision as of 20:55, 26 May 2026
Line 145:		Line 145:
	\| traditional_geography =		\| traditional_geography =
	\| anecdotes =		\| anecdotes =
			\| references = <references/>
	}}		}}

	~~== References ==~~
	~~<references/>~~

	[[Category:Plants]]		[[Category:Plants]]

Dandelion

MDElliottMD — Tue, 26 May 2026 20:28:02 GMT

home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

Show changes

Peppermint

MDElliottMD — Tue, 26 May 2026 20:28:01 GMT

home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

Show changes

Lemon balm

MDElliottMD — Tue, 26 May 2026 20:28:00 GMT

home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

Show changes

Lavender

MDElliottMD — Tue, 26 May 2026 20:27:59 GMT

home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

Show changes

Chinese licorice

MDElliottMD — Tue, 26 May 2026 20:27:50 GMT

home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

Show changes

Pissenlit

MDElliottMD — Tue, 26 May 2026 20:08:47 GMT

home-claude: redirect to Dandelion

New page

#REDIRECT [[Dandelion]]

Pu gong ying

MDElliottMD — Tue, 26 May 2026 20:08:46 GMT

home-claude: redirect to Dandelion

New page

#REDIRECT [[Dandelion]]

Dandelion leaf

MDElliottMD — Tue, 26 May 2026 20:08:45 GMT

home-claude: redirect to Dandelion

New page

#REDIRECT [[Dandelion]]

Dandelion root

MDElliottMD — Tue, 26 May 2026 20:08:44 GMT

home-claude: redirect to Dandelion

New page

#REDIRECT [[Dandelion]]

Taraxacum officinale

MDElliottMD — Tue, 26 May 2026 20:08:43 GMT

home-claude: redirect to Dandelion

New page

#REDIRECT [[Dandelion]]

Dandelion

MDElliottMD — Tue, 26 May 2026 20:08:36 GMT

home-claude: Herb #10 Dandelion initial publish (Q1-Q3 resolved; 5 PMIDs verified + 1974 Racz-Kotilla added; binomial italics applied)

New page

{{PlantMedTemplate
| binomial = Taraxacum officinale
| family = Asteraceae
| native_range = Originally native to Eurasia and North Africa; now one of the most globally distributed plants in the world, present on every inhabited continent following dispersal with European colonization. Grows wild in grassland, roadsides, disturbed ground, and lawns throughout the temperate zone; cultivated commercially for medicinal and culinary supply in Germany and France.
| parts_used = Leaves (diuretic; harvested before flowering for highest bitter-principle content); root (hepatic bitter; dug in autumn from second-year plants for highest inulin content); flowers (minor; folk wine and syrup).
| images =
| intro = ''Taraxacum officinale'' G.H. Weber ex Wiggers -- dandelion -- is a perennial composite herb of Eurasian origin, now distributed across every inhabited continent and recognized by virtually every person alive, most of whom have at some point scattered its seeds from a spherical white clock. The French long ago named it pissenlit -- wet-the-bed -- which is an accurate clinical description of its principal medicinal action in the leaf, and it is this frankness of folk nomenclature that most concisely captures the herb's place in medicine: a plant dismissed as a weed by every suburban lawn, carrying a clinical evidence base in diuresis that most commercially marketed diuretic herbs cannot match, with the additional distinction of replenishing in the leaf the very potassium that synthetic diuretics strip away.

| traditional_uses = The earliest written records of dandelion in medicine come from 11th-century Arabic physicians -- Ibn Sina listed dandelion leaf in pharmacopoeial works -- and from the Welsh Physicians of Myddfai, a 13th-century medical guild whose manuscripts record it for liver and digestive complaints.{{citation needed}} By the 17th century ''T. officinale'' was established in every European herbal, universally respected as a hepatic bitter, a diuretic, and a spring tonic food -- the tender young leaves gathered from fields before the first flowering and eaten in salad as an annual seasonal cleanse.

The name is a corruption of the French dent-de-lion (lion's tooth), referring to the deeply ragged leaf margins; in English it became "dandelion" by the 16th century. The French pissenlit captured the leaf's diuretic force with characteristic directness; contemporary French herbalists still use the term without embarrassment, as an accurate pharmacological description rather than a vulgarity.

Nicholas Culpeper in 1653 recorded dandelion for "opening obstructions of the liver, gall, and spleen," for jaundice, and as "a sovereign remedy against the evil disposition of the body, proceeding from the badness of the blood."{{citation needed}} These indications -- liver, spleen, fluid, blood quality -- are precisely those that the Western alterative tradition has assigned to dandelion root for the four centuries since Culpeper, with remarkable consistency across German, French, British, and American herbal schools.

'''Chinese medicine: Pu Gong Ying (蒲公英)'''

In Chinese medicine the principal species is ''Taraxacum mongolicum'' (sometimes listed as ''T. sinicum''), though ''T. officinale'' is accepted as an equivalent in most contemporary pharmacopoeias. Under the name Pu Gong Ying, it is classified as bitter and sweet in flavor, cold in nature, entering the liver and stomach meridians. Its principal TCM indications are clearing heat and relieving toxicity -- the diagnostic category covering acute inflammatory and infectious conditions: breast abscess and mastitis (one of the most historically consistent indications in TCM practice for this herb), acute sore throat and tonsillitis, infected eyes, jaundice from damp-heat in the liver, and intestinal infection with heat signs.{{citation needed}} The TCM mastitis indication -- Pu Gong Ying as a primary herb for acute lactation mastitis, applied both internally as a decoction and topically as a poultice of fresh crushed leaf -- is among the most specific and consistent indications in the Chinese Materia Medica and has ethnopharmacological parallels in European practice (fresh dandelion leaf poultice for skin inflammation and swelling).

'''Native American and post-colonial American use'''

As ''T. officinale'' spread with European colonization, indigenous peoples throughout North America adopted it rapidly as it naturalized across the continent. Multiple nations used it for kidney, liver, and digestive complaints -- applications consistent with the introduced European knowledge system -- suggesting either independent discovery of the same pharmacological effects or rapid adoption of European herbal knowledge through trade contact.{{citation needed}}

'''Food tradition'''

Dandelion occupies an unusual dual role as food and medicine. Spring dandelion greens -- young leaves gathered before flowering, when bitter principles are concentrated and the leaves are most nutritionally dense -- are among the most nutritionally complete wild greens available in temperate climates, higher in vitamins A, C, and K, and in calcium, iron, and potassium, than most cultivated vegetables.{{citation needed}} Dandelion coffee -- roasted dried root decoction -- became a wartime staple in Britain and Europe during both World Wars when coffee was rationed, and remains a gentle, caffeine-free bitter digestive tonic in current herbal practice. In France, ''pissenlit au lard'' (dandelion greens with lardons and hot vinegar dressing) is a Burgundian spring classic with a history traceable to medieval monastic cooking.

| botany = ''Taraxacum officinale'' G.H. Weber ex Wiggers is placed in tribe Cichorieae (formerly Lactuceae), subfamily Cichorioideae, family Asteraceae. The species epithet officinale (of the dispensary) signals long apothecary use; the genus name derives from the Arabic tarakhshagun or the medieval Latin corruption of it, meaning bitter herb. ''Taraxacum'' is an enormously complex genus: depending on the taxonomic authority, it contains anywhere from 60 to 2,000 or more microspecies, many of which are apomictic (reproducing without fertilization, generating clonal lineages). Most commercial medicinal supply and most clinical research uses ''T. officinale'' in the broad, aggregate sense rather than any single microspecies; pharmacopoeial monographs accept this broad usage.

The plant is a perennial forming a basal rosette of deeply pinnately lobed leaves -- the lobes giving the lion's-tooth shape -- growing from a deep taproot that can reach 30 to 50 cm in established plants. The leaves are glabrous to slightly hairy; in cultivated populations they may be less deeply lobed. Hollow, leafless scapes (flower stalks) arise singly from the crown, each bearing a single bright golden composite head of ray florets only (no disk florets); this morphology distinguishes it from most other yellow composites. The well-known globular gray-white seed head (the "clock") consists of the achenes with their attached pappus (feathery parachute structures) that allow wind dispersal over considerable distances. A single plant may produce 2,000 to 12,000 seeds per year, a reproductive strategy that explains both its global success and suburban gardeners' despair.

The medicinal parts are harvested by part and season: leaves before first flowering in spring (highest bitter-principle and potassium content; preferred for diuretic use), root in autumn from second-year plants (highest inulin content; preferred for hepatic use). The spring-leaf and autumn-root distinction is not merely traditional but is pharmacologically grounded in the plant's seasonal allocation of primary metabolites.

Closely related: ''Taraxacum mongolicum'' (Pu Gong Ying; principal TCM medicinal species; used pharmacopoeially as equivalent to ''T. officinale'').

| constituents = '''Leaf constituents'''

The leaf is the more nutritionally dense and diuretically active part. Principal constituents include sesquiterpene lactones (taraxacin and related compounds, responsible for the bitter taste), triterpenes, polysaccharides, coumarins, carotenoids (beta-carotene and lutein; source of the leaf's nutritional vitamin-A equivalents), vitamins C and K, and, notably, minerals at concentrations that distinguish it from most vegetables: potassium content is among the highest of any leafy green, with documented values of 370 to 500 mg per 100 g fresh weight.{{citation needed}} This mineral composition is the pharmacological basis of dandelion leaf's unique advantage among diuretics: it replenishes the urinary potassium losses it induces, preventing the hypokalemia associated with synthetic loop and thiazide diuretics.

'''Root constituents'''

The root holds a different pharmacological profile. Inulin -- a fructooligosaccharide prebiotic polysaccharide -- constitutes up to 40 percent of dry root weight in autumn-harvested material, falling to 1 to 2 percent in spring (when it has been consumed in new-growth production).{{citation needed}} This seasonal variation is the pharmacological rationale for the traditional autumn-harvest preference. Taraxacoside, the principal bitter sesquiterpene glycoside of the root, contributes to the bitter-tonic and mild laxative actions. Phenolic acids (chicoric acid, caffeic acid derivatives), triterpenes (taraxasterol, taraxerol), and polyacetylenes complete the profile. Mineral content in the root, while lower per gram than the leaf, is still significant.

| pharmacodynamics = '''Diuretic mechanism (leaf)'''

The leaf's diuretic action is classified as aquaretic -- meaning it increases urine volume and sodium excretion without proportional potassium loss -- distinguishing it from synthetic diuretics (loop diuretics, thiazides) that cause significant potassium depletion. The mechanism is thought to involve inhibition of tubular sodium reabsorption by sesquiterpene lactone constituents, but the precise renal tubular pharmacology has not been fully characterized at the receptor level.{{citation needed}} The high potassium content of the leaf preparation further buffers any net potassium loss, contributing to the clinically observed potassium-sparing profile.

'''Hepatic and cholagogue mechanism (root)'''

The bitter sesquiterpene compounds (taraxacoside and related lactones) stimulate bile secretion from the liver and gallbladder contraction -- the cholagogue action that underlies the hepatic-bitter tonic use. This mechanism is consistent with the pharmacology of other bitter Asteraceae (chicory, artichoke) and with the TCM clearing-heat-from-liver-channel framing of the same traditional indication. In animal models, dandelion root extracts have demonstrated hepatoprotective effects against carbon tetrachloride-induced hepatotoxicity and against acetaminophen toxicity, consistent with antioxidant and anti-inflammatory mechanisms.{{citation needed}}

'''Anti-inflammatory mechanism'''

Polyphenolic compounds in the leaf and root (including chicoric acid, caffeic acid derivatives, and flavonoids) inhibit pro-inflammatory signaling cascades in cell-culture models, including reduction of LPS-stimulated NF-kB activation and suppression of pro-inflammatory cytokine release.<ref name="jeon2017">Jeon D, Kim SJ, Kim HS. "Anti-inflammatory evaluation of the methanolic extract of ''Taraxacum officinale'' in LPS-stimulated human umbilical vein endothelial cells." BMC Complement Altern Med. 2017;17(1):508. PMID 29187173.</ref> Whether these in vitro effects translate to clinically meaningful anti-inflammatory activity in human tissue remains to be established in powered clinical trials.

'''Prebiotic mechanism (root inulin)'''

Inulin is a well-characterized prebiotic: it selectively promotes the growth of beneficial gut microbiota (principally ''Bifidobacterium'' and ''Lactobacillus'' species) by serving as a fermentable substrate for these organisms while being resistant to digestion by human gut enzymes. The effect is dose-dependent and well-established for inulin regardless of botanical source; dandelion root is one of the most concentrated natural sources of inulin outside chicory root (''Cichorium intybus'') and Jerusalem artichoke (''Helianthus tuberosus'').{{citation needed}}

| indications = '''Diuretic activity: human clinical evidence'''

Clare, Conroy, and Spelman (2009) conducted a single-day human clinical study in 17 healthy volunteers, administering an extract of ''Taraxacum officinale'' leaf (8 ml per dose from a 1:5 infusion) three times over seven hours. Urine volume and urinary frequency increased significantly between the first and second doses and between the second and third doses relative to pre-treatment baseline, demonstrating acute diuretic activity in humans. Urinary excretion of potassium was not significantly depleted, consistent with the leaf's high potassium content counterbalancing urinary losses.<ref name="clare2009">Clare BA, Conroy RS, Spelman K. "The diuretic effect in human subjects of an extract of ''Taraxacum officinale'' folium over a single day." J Altern Complement Med. 2009;15(8):929-934. PMID 19678785.</ref><ref name="raczkotilla1974">Racz-Kotilla E, Racz G, Solomon A. "The action of ''Taraxacum officinale'' extracts on the body weight and diuresis of laboratory animals." Planta Med. 1974;26(3):212-217. PMID 4427955.</ref> This study is single-day and uncontrolled (no parallel placebo arm); it establishes acute diuretic activity but does not address long-term efficacy or comparative effectiveness against synthetic diuretics.

No large-scale randomized controlled trials of dandelion leaf for clinical edema, hypertension, or fluid retention have been published. The clinical evidence base for the diuretic indication is consistent but limited in scale and rigor relative to conventional diuretics.

'''Hepatic and alterative uses: traditional and preclinical evidence only'''

The hepatic-tonic, alterative, and liver-cleansing indications that constitute the principal traditional use of dandelion root do not have a randomized clinical trial evidence base in humans. Animal models show hepatoprotective effects against chemical hepatotoxins; the bitter-tonic mechanism is pharmacologically well-grounded; the cholagogue action is consistent with the class pharmacology of sesquiterpene bitters. The absence of clinical trial data reflects the general underfunding of hepatic herbal medicine research rather than any evidence of inefficacy, but the distinction between traditional use supported by preclinical data and use supported by clinical trials should be maintained in patient-facing communication.

'''Anticancer activity: in vitro studies only'''

Ovadje and colleagues have published a series of in vitro studies demonstrating that aqueous dandelion root extract selectively induces apoptosis in human leukemia cell lines through both intrinsic and extrinsic pathways, without significant toxicity to normal peripheral blood mononuclear cells.<ref name="ovadje2011">Ovadje P, Chatterjee S, Griffin C, Tran C, Hamm C, Pandey S. "Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract." J Ethnopharmacol. 2011;133(1):86-91. PMID 20849941.</ref><ref name="ovadje2012">Ovadje P, Hamm C, Pandey S. "Efficient induction of extrinsic cell death by dandelion root extract in human chronic myelomonocytic leukemia (CMML)." PLoS One. 2012;7(2):e30604. PMID 22363452.</ref> These are laboratory findings in cell lines; they do not constitute clinical evidence of anticancer efficacy in humans. No clinical trials of dandelion root extract for cancer treatment have been completed or published. These findings are scientifically interesting and warrant further investigation but should not be represented as clinical evidence of therapeutic effect.

| preparations = Leaf infusion (tea): 4 to 8 g fresh or dried leaves per cup of hot water, steeped covered (volatile constituents are modest; the cover prevents steam loss rather than oil loss). Taken 2 to 3 times daily for diuretic and tonic use; or fresh leaves as salad greens (the traditional spring tonic form, maximally nutritious and minimally processed).

Root decoction: 5 to 10 g dried root in 500 ml water, simmered covered for 15 to 20 minutes; strained and drunk in 2 to 3 portions through the day. The preferred preparation for hepatic-bitter and cholagogue use; suited to the autumn-harvested root with its peak inulin content.

Root tincture: 1:5 in 40 to 45 percent ethanol from dried root; 2 to 5 ml three times daily.

Roasted root "coffee": dried root roasted until dark brown (approximately 200 degrees Celsius, 30 minutes); ground and prepared by decoction or percolation as a coffee substitute. The roasting converts much of the inulin to simpler fructose units and develops the characteristic dark, slightly bitter flavor; the hepatic bitter action is retained at reduced intensity. A gentle daily liver tonic and caffeine-free coffee alternative with a continuous history from World War II rationing.

Root powder: 2 to 4 g per day in capsule or tablet form; convenient standardized option.

| dosing = '''Leaf (diuretic, tonic)'''

Infusion: 4 to 8 g dried leaf per cup, 2 to 3 times daily. Fresh leaf as salad: no formal dose ceiling; traditional seasonal use is ad libitum.

Tincture (1:5 in 40 percent ethanol): 2 to 5 ml three times daily.

'''Root (hepatic-bitter, cholagogue, prebiotic)'''

Decoction: 5 to 10 g dried root per day in divided doses. Tincture (1:5): 2 to 5 ml three times daily. Powder: 2 to 4 g per day.

The traditional distinction between spring-leaf use (diuretic, nutritive tonic) and autumn-root use (hepatic-bitter, prebiotic) reflects genuine pharmacological differences in the plant across seasons and should be preserved in practice where possible.

'''Recreational dose ladder'''

Dandelion has no recreational or psychoactive profile in any documented tradition. Neither the leaf nor the root produces altered consciousness, euphoria, sedation, or any psychoactive effect at any accessible dose. The bitter taste at higher leaf or root doses is limiting; above 10 to 15 g of dried root per day, mild nausea and diarrhea occur as the dose-limiting gastrointestinal effects. No dose ladder is warranted.

| pharmacokinetics = The pharmacokinetics of ''T. officinale'' constituents have not been well characterized. Taraxacoside and related sesquiterpene lactones are likely absorbed from the gastrointestinal tract and undergo hepatic metabolism; the kinetics are not documented to the same standard as pharmaceutical preparations. Inulin from the root is not absorbed -- it passes undigested to the large intestine where it is fermented by colonic microbiota; this is entirely the intended pharmacological mechanism for its prebiotic action rather than a bioavailability problem. Polyphenolic compounds (chicoric acid, caffeic acid derivatives) are absorbed in part from the small intestine and undergo conjugation and methylation by gut enzymes and hepatic CYP enzymes.{{citation needed}}

| interactions = Lithium: dandelion leaf's diuretic action reduces renal lithium clearance (as does any diuretic); this can elevate lithium plasma levels into the toxic range. Patients taking lithium should not use dandelion leaf preparations without medical supervision and lithium-level monitoring.{{citation needed}}

Potassium-sparing diuretics and ACE inhibitors: dandelion leaf's potassium-retaining character combined with potassium-sparing agents (spironolactone, eplerenone) or ACE inhibitors (which reduce urinary potassium excretion) could theoretically produce hyperkalemia in vulnerable patients. The risk is low at typical leaf-infusion doses but warrants monitoring in patients with renal impairment or on potassium-sparing regimens.

Antidiabetic medicines: dandelion has mild blood-glucose-lowering properties in animal models; additive hypoglycemic effect is possible with insulin and oral antidiabetic agents. Monitor blood glucose in diabetic patients who begin regular dandelion use.

Anticoagulants (warfarin): dandelion leaves are very high in vitamin K. Patients on warfarin anticoagulation whose vitamin K intake changes significantly (including by adding large quantities of dandelion leaf to the diet) may experience INR instability. Consistency of intake is more important than avoidance.

| interactionsummary = Lithium: diuresis raises lithium levels (monitor). High vitamin K in leaf: INR variability with warfarin. Additive hypoglycemia possible with antidiabetic medicines.

| counseling = The distinction between leaf and root preparations should be communicated clearly: the diuretic action resides principally in the leaf, and the hepatic-bitter and prebiotic actions in the root. A patient seeking fluid-retention relief should use the leaf infusion; a patient seeking liver support, digestive bitters, or prebiotic gut support should use the root decoction or roasted root.

The potassium-sparing quality of the dandelion leaf diuresis is genuinely clinically relevant and worth explaining to patients who have previously been told to avoid diuretics because of potassium concerns: dandelion leaf does not cause the potassium depletion associated with furosemide or hydrochlorothiazide. This distinction is well-grounded pharmacologically, though the clinical trial evidence is limited in scale.

The anticancer cell-line findings should not be communicated to patients as evidence of clinical efficacy. The in vitro data are preliminary and interesting; no clinical benefit in cancer treatment has been established. Patients with cancer who are interested in dandelion root for general liver support or digestive use (reasonable traditional indications) should be informed of this distinction.

===Safety===

Dandelion is among the safest herbs in the Western pharmacopoeia for adults, children, and in pregnancy. Serious adverse events are not documented in the clinical or case-report literature at standard dietary or medicinal doses.

Gallstones: the root's cholagogue (gallbladder-stimulating) action is the principal safety concern. In patients with known gallstones, particularly large stones or any degree of bile duct obstruction, stimulating gallbladder contraction can precipitate biliary colic. Dandelion root preparations should be used with caution in patients with known cholelithiasis and are contraindicated in patients with obstructive jaundice or bile duct obstruction.

Asteraceae allergy: dandelion is in the same plant family as ragweed (''Ambrosia'' spp.), chamomile, and chrysanthemum. Patients with documented Asteraceae contact or inhalant allergy may have cross-reactive responses to dandelion; this is most relevant for topical use of fresh plant material. Oral ingestion of dandelion in Asteraceae-allergic individuals is generally well-tolerated but warrants initial caution.

Pregnancy and lactation: dandelion leaf and root are used as food and tonic herbs in traditional midwifery without reported harm; the plant is among the herbs most consistently classified as safe in pregnancy at dietary doses. Large-dose medicinal preparations have not been formally evaluated in pregnancy trials.

===Regulatory===

'''Germany'''

German Commission E: dandelion root with herb (Taraxaci radix cum herba) approved for disturbances of bile flow, stimulation of diuresis, loss of appetite, and dyspepsia.

'''European Union'''

EMA HMPC: positive assessment for traditional use of dandelion root and herb for symptomatic treatment of minor digestive disorders (dyspepsia, bloating, flatulence) and as adjuvant for increased urinary output in minor urinary complaints. Traditional use listing under the EU Traditional Herbal Medicinal Products Directive.<ref name=ema-taraxacum>European Union herbal monograph on ''Taraxacum officinale'' F.H. Wigg., radix. EMA/HMPC/475726/2020. Committee on Herbal Medicinal Products (HMPC). https://www.ema.europa.eu/en/medicines/herbal/taraxaci-officinalis-radix</ref>

'''United States'''

Dandelion root and leaf: GRAS (generally recognized as safe) as food; sold as a dietary supplement under DSHEA without FDA evaluation of therapeutic claims.

'''United Kingdom'''

MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.

}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Hepatoprotective herbs]]
[[Category:Urological herbs]]
[[Category:Diuretic herbs]]
[[Category:Western clinical herbs]]
[[Category:TCM herbs]]

Category:Diuretic herbs

MDElliottMD — Tue, 26 May 2026 20:07:19 GMT

home-claude: create Category:Diuretic herbs (approved 2026-05-25; dandelion publish Q1)

New page

A '''diuretic herb''' is a plant medicine that increases urine volume and urinary excretion, used traditionally for fluid retention, minor urinary complaints, urinary-tract supportive care, and as an adjunct in kidney-stone prevention by increasing urinary flow. The principal mechanism of most herbal diuretics is aquaretic: an increase in glomerular filtration rate or inhibition of tubular reabsorption without the proportional potassium loss (hypokalemia) associated with synthetic loop diuretics (furosemide) and thiazides (hydrochlorothiazide).

The most clinically evidenced herbal diuretic is dandelion leaf (''Taraxacum officinale''): a human clinical study by Clare and colleagues (2009) demonstrated significant acute increases in urine volume and urinary frequency following three doses of a dandelion leaf extract over seven hours, with no significant reduction in urinary potassium -- consistent with the leaf's high potassium content counterbalancing urinary losses. The aquaretic mechanism distinguishes dandelion from synthetic diuretics and is the pharmacological basis of the herb's traditional use for fluid-retention states without the associated electrolyte risk.

The diuretic-herb category includes: the classical aquaretics (dandelion leaf, couch grass, cleavers, corn silk, goldenrod), the kidney-stone-prevention and urinary-tract-soothing herbs (uva ursi, buchu, juniper), and herbs with secondary diuretic action alongside a primary indication elsewhere (nettle, parsley seed, celery seed). Several herbs in this category also appear in [[:Category:Urological_herbs|urological herbs]] for their overlap with urinary-tract infection and prostate-related indications.

== Members indexed ==

Dandelion (''Taraxacum officinale'', leaf preparation).

== Notes on scope ==

The pharmaceutical diuretics ([[:Category:Loop_diuretics|loop diuretics]], [[:Category:Thiazides|thiazides]], potassium-sparing diuretics) are listed under their own categories. This category covers the plant-medicine tradition of diuretic herbs as recognised in the British Herbal Pharmacopoeia, the German Commission E, and the EMA HMPC traditional-use assessments.

== About these pages ==

[[:Category:CuratedCategoryPage|Curated category pages]] in the Pharmacopedia are written and maintained by the editorial team. Members are listed when a full page exists; herbs with planned pages will be added on publication.

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:CuratedCategoryPage]]

Peppermint

MDElliottMD — Tue, 26 May 2026 19:18:30 GMT

home-claude: fix hatnote pipe + remove duplicate empty template fields

← Older revision		Revision as of 19:18, 26 May 2026
Line 1:		Line 1:
	{{hatnote\|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See [[#~~Botany and identification\|~~Botany and identification]] for the safety warning.}}		{{hatnote\|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See the [[#Botany and identification]] section for the full safety warning.}}
	{{PlantMedTemplate		{{PlantMedTemplate
	\| name = Peppermint		\| name = Peppermint
Line 151:		Line 151:
	Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.		Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.

	~~\| history =~~
	~~\| effects =~~
	~~\| traditional_geography =~~
	~~\| anecdotes =~~
	}}		}}

Mentha × piperita

MDElliottMD — Tue, 26 May 2026 19:07:19 GMT

home-claude: redirect to Peppermint (proper hybrid × symbol)

New page

#REDIRECT [[Peppermint]]

Peppermint oil

MDElliottMD — Tue, 26 May 2026 19:07:04 GMT

home-claude: redirect to Peppermint

New page

#REDIRECT [[Peppermint]]

Mentha piperita

MDElliottMD — Tue, 26 May 2026 19:07:03 GMT

home-claude: redirect to Peppermint

New page

#REDIRECT [[Peppermint]]

Mentha x piperita

MDElliottMD — Tue, 26 May 2026 19:07:02 GMT

home-claude: redirect to Peppermint

New page

#REDIRECT [[Peppermint]]

Peppermint

MDElliottMD — Tue, 26 May 2026 19:05:35 GMT

home-claude: Herb #9 Peppermint initial publish (Q1-Q3 resolved; 8 PMIDs verified; binomial italics applied)

New page

{{hatnote|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See [[#Botany and identification|Botany and identification]] for the safety warning.}}
{{PlantMedTemplate
| name = Peppermint
| binomial = Mentha × piperita
| family = Lamiaceae
| native_range = Not native to any wild habitat: peppermint is a sterile hybrid and does not reproduce from seed. First recorded in England in the 17th century, probably arising spontaneously in cultivated mint fields near Mitcham, Surrey. Now cultivated worldwide throughout the temperate zone; principal commercial producers are the United States (Pacific Northwest and Indiana), India, and China.
| plant_part = Aerial parts (leaves and flowering tops); essential oil distilled from fresh herb; enteric-coated capsules of the essential oil for pharmaceutical use.
| image =
| intro = ''Mentha x piperita'' L. -- peppermint -- is a sterile hybrid of watermint (''Mentha'' aquatica) and spearmint (''Mentha spicata'') first documented in the herb gardens of 17th-century England. It reproduces only by vegetative spread and would disappear without cultivation; instead it has become the most widely grown aromatic herb in the world, its menthol extracted in quantities sufficient to scent a global industry of confectionery, personal care, and pharmaceuticals. Among medicinal herbs it holds an unusual distinction: enteric-coated peppermint oil capsules are supported by a Cochrane systematic review of nine randomized controlled trials reporting a number needed to treat of 2.5 for irritable bowel syndrome -- one of the strongest evidence-backed botanical indications in gastrointestinal medicine.

| history = Mint is one of the oldest plants in the human medicinal record. Dried mint leaves have been recovered from Egyptian tombs dated to approximately 1000 BCE; the Romans cultivated mint so extensively across their empire that Pliny the Elder complained they planted it everywhere.{{citation needed}} The Greek physician Dioscorides recorded multiple mint species and their uses for flatulence, nausea, and the suppression of vomiting; Hippocrates had written of mint before him. In the Arab world, the physician Ibn Sina noted mint's digestive and carminative properties in the Canon of Medicine. By the medieval period mint was among the universal European monastery garden plants, appearing in every hortus conclusus alongside sage, rosemary, and lavender.

What none of these traditions knew, because it did not yet exist, was peppermint. ''Mentha x piperita'' is a hybrid -- a cross between watermint and spearmint -- that arose, or was first recognized, in England in the 17th century, likely in the commercial mint-growing fields around Mitcham in Surrey, which became the center of English peppermint cultivation and remained so through the 19th century. John Ray, the English naturalist, first formally described peppermint as a distinct plant in 1696.{{citation needed}} The English cultivated it first; then the Americans took it -- particularly the farmers of Chautauqua County, New York and later the Columbia River basin -- and by the 19th century peppermint was a transatlantic commodity. By the 20th century it was a global industrial crop, its oil distilled in tonnage for the tobacco, confectionery, and oral hygiene industries, and the pharmacognosists were beginning to work out exactly why it did what it had always done to a troubled gut.

The therapeutic pivot came in stages. Commission E in Germany approved peppermint oil for spasmodic complaints of the upper gastrointestinal tract in 1990, grounded in traditional use and the available pharmacological rationale. The pharmaceutical form -- enteric-coated peppermint oil capsules formulated to survive the stomach acid and release their contents in the small intestine -- was the key innovation; Colpermin appeared in the 1980s and accumulated clinical trial data through the 1990s and 2000s. The Cochrane Collaboration's 2014 systematic review was the culmination of that evidence, and it placed peppermint oil among the most rigorously substantiated botanical interventions in gastroenterology.

| taxonomy = ''Mentha x piperita'' L. belongs to tribe Mentheae, family Lamiaceae. The multiplication sign in the binomial (x) denotes hybrid origin: the parents are ''Mentha'' aquatica (watermint) and ''Mentha spicata'' (spearmint). The hybrid is triploid and entirely sterile -- it sets no viable seed and propagates exclusively by vegetative means (rhizomes and cuttings). The x piperita epithet (pepper-mint) refers to the hot-cool-pungent character of the fresh leaf, distinct from the milder spearmint parent.

The genus ''Mentha'' comprises approximately 25 recognized species and a very large number of hybrids, cultivars, and named varieties; the genus is taxonomically complex, and menthol content varies considerably across species and cultivars. Medically and commercially significant species include:

''Mentha'' aquatica (watermint): one parent of peppermint; grows in wet habitats; high linalool content; mild medicinal use.

''Mentha spicata'' (spearmint): the other parent; carvone-dominant rather than menthol-dominant; gentler, less cooling; the spearmint of culinary use and the safer option for children and for those who do not tolerate peppermint's LES-relaxing effect.

''Mentha'' arvensis (corn mint, Japanese peppermint): the dominant commercial source of natural menthol crystals; native to Asia; the oil from this species is far higher in menthol (70 to 90 percent) than peppermint oil (35 to 55 percent) and is the source of most of the menthol in commercial cough drops, mentholated cigarettes, and topical pain preparations.

''Mentha'' pulegium (pennyroyal): HIGHLY TOXIC. Pulegone-rich; historically used as a folk abortifacient; cases of maternal fatality and severe hepatic failure have been reported following ingestion of pennyroyal oil as an abortifacient agent.{{citation needed}} Pennyroyal should never be used as a substitute for peppermint in any context; the two plants have been confused in commercial herbal markets with fatal consequences.

The medicinal parts of M. x piperita are the aerial parts -- leaves and flowering tops -- harvested before full flowering. The essential oil is steam-distilled from fresh herb; genuine peppermint oil should contain menthol at 35 to 55 percent, distinguishing it from the lower-grade lavandin oil in the lavender trade's parallel adulteration problem.

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Peppermint's principal traditional indications mirror its modern evidence base with unusual fidelity: flatulence and bloating, digestive cramping and colic, nausea and vomiting, dyspepsia, headache (particularly the common tension headache with a frontal or temporal distribution), nasal congestion from colds, and muscle pain. The herb has been used for these purposes in continuous Western practice from at least the 18th century, when peppermint tea became the commonest domestic remedy for an upset stomach in Britain and America. The inhalational use for nasal congestion -- peppermint steam over hot water, peppermint oil rubbed on the chest or dissolved in a steam inhaler -- has equal continuity. The topical application to the temple and forehead for headache appears in 18th- and 19th-century domestic medicine texts and was given its first controlled clinical evidence base by Gobel in 1996.

'''TCM: Bo He (薄荷)'''

Peppermint is used in Chinese medicine under the name Bo He, though the plant sourced in Chinese practice is frequently ''Mentha'' haplocalyx or other Asian ''Mentha'' species rather than M. x piperita; the volatile-oil chemistry is sufficiently similar for the indications to overlap. In the TCM framework, Bo He is classified as pungent and cool, entering the lung and liver meridians. Its primary indications are wind-heat exterior patterns (early common cold or influenza with fever, sore throat, headache) where it disperses the pathogenic wind-heat; it also clears the head and eyes for wind-heat-related headache and red eyes, and moves liver qi stagnation for irritability and distention. In formulae, it is frequently combined with Forsythia (Lian Qiao) and Lonicera (Jin Yin Hua) in standard wind-heat formulas such as Yin Qiao San.{{citation needed}}

'''Ayurvedic medicine (Pudina)'''

Peppermint is used in Ayurvedic medicine as Pudina, described as pungent, slightly bitter, and cooling in action; it pacifies kapha and vata doshas while having mixed effects on pitta. Principal Ayurvedic indications are digestive complaints -- dyspepsia, nausea, vomiting -- and febrile conditions where its diaphoretic action is valued. It is among the aromatics used in Ayurvedic churnas (herbal powders) for digestive support.{{citation needed}}

'''Islamic medicine (Na'na)'''

Mint was known in Arabic-speaking medicine as Na'na (نعناع) and classified as cool and drying in the Galenic-Islamic temperament system; Ibn Sina described it for digestion, fevers, headache, and nausea in the Canon of Medicine, consistent with its Dioscoridean antecedents.{{citation needed}}

| pharmacology = '''Menthol: the principal active constituent'''

Peppermint essential oil contains menthol at 35 to 55 percent of total volatile oil, menthone at 10 to 40 percent, menthyl acetate, isomenthone, 1,8-cineole, and trace amounts of pulegone (significantly higher in pennyroyal and in some lavandin adulterants).{{citation needed}}

Menthol exerts its principal therapeutic actions through two distinct receptor mechanisms.

Voltage-gated calcium channel blockade in gastrointestinal smooth muscle: menthol and whole peppermint oil inhibit L-type calcium channels in intestinal smooth muscle, reducing calcium-dependent contraction and relaxing GI tone. This was first demonstrated in a pharmacological study by Hawthorn and colleagues in 1988<ref name="hawthorn1988">Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac smooth muscle." Aliment Pharmacol Ther. 1988;2(2):101-118. PMID 2856502.</ref> and confirmed in human colonic smooth muscle by Amato and colleagues in 2014.<ref name="amato2014">Amato A, Liotta R, Mule F. "Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action." Eur J Pharmacol. 2014;740:295-301. PMID 25046841.</ref> The L-type calcium channel mechanism accounts for menthol's antispasmodic action in the irritable bowel -- precisely the mechanism that explains why an enteric-coated capsule formulation that delivers the oil to the small and large intestine (bypassing the stomach) is necessary for IBS treatment.

Transient receptor potential melastatin 8 (TRPM8) activation: menthol is the principal natural ligand of TRPM8, the cold-sensitive ion channel responsible for the sensation of coolness (and, paradoxically, of cold-induced burning at high concentrations). TRPM8 activation in sensory neurons is the basis of peppermint's cooling sensation on the skin and mucous membranes, and contributes to its topical analgesic effect in tension headache -- initial TRPM8 activation followed by desensitization leads to reduced pain signaling in the same manner that capsaicin (TRPV1 agonist) produces topical analgesia via TRPV1 desensitization.<ref name="mckemy2002">McKemy DD, Neuhausser WM, Julius D. "Identification of a cold receptor reveals a general role for TRP channels in thermosensation." Nature. 2002;416(6876):52-58. PMID 11882888.</ref><ref name="bautista2007">Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI. "The menthol receptor TRPM8 is the principal detector of environmental cold." Nature. 2007;448(7150):204-208. PMID 17538622.</ref>

Antimicrobial activity: peppermint essential oil demonstrates broad-spectrum antibacterial and antifungal activity in vitro, including against ''Helicobacter pylori'', ''Candida albicans'', methicillin-resistant ''Staphylococcus aureus'', and Escherichia coli; the mechanism involves menthol's disruption of microbial cell membrane integrity.{{citation needed}}

Choleretic activity: peppermint oil stimulates bile secretion from the gallbladder and hepatic bile production; this contributes to its efficacy in functional dyspepsia and gallbladder-related upper GI symptoms and is the pharmacological basis of the Commission E approval for bile duct and gallbladder complaints.{{citation needed}}

| clinical_evidence = '''Irritable bowel syndrome (enteric-coated peppermint oil capsules)'''

The evidence for enteric-coated peppermint oil in IBS is the strongest clinical evidence base of any herbal medicine in gastroenterology. The formulation is critical: non-enteric-coated preparations dissolve in the stomach, causing upper GI side effects (heartburn, nausea from premature LES relaxation) without delivering active oil to the target site in the small and large intestine. Enteric-coated capsules bypass the stomach and release their contents only in the more alkaline intestinal environment.

Khanna and colleagues (2014) conducted a systematic review and meta-analysis of nine randomized, placebo-controlled trials (total n = 726) of enteric-coated peppermint oil for IBS. Global symptom improvement was significantly greater in the peppermint group; the pooled relative risk for global improvement was 2.23 (95 percent CI 1.78 to 2.81), corresponding to a number needed to treat of 2.5 -- a remarkably strong treatment effect for a botanical intervention in a notoriously treatment-resistant condition.<ref name="khanna2014">Khanna R, MacDonald JK, Levesque BG. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." J Clin Gastroenterol. 2014;48(6):505-512. PMID 24100754.</ref>

Among the constituent trials, Cappello and colleagues (2007) randomized 57 patients with IBS to peppermint oil (Mintoil) 187 mg three times daily in enteric-coated capsules or placebo for four weeks; 75 percent of the treated group achieved at least 50 percent reduction in total symptom score, compared with 38 percent in the placebo group. Abdominal pain, distention, stool urgency, flatulence, and borborygmi all improved significantly in the peppermint group.<ref name="cappello2007">Cappello G, Spezzaferro M, Grossi L, Marzio L, Marzio L. "Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial." Dig Liver Dis. 2007;39(6):530-536. PMID 17420159.</ref>

'''Tension headache (topical peppermint oil)'''

Gobel and colleagues (1996) conducted a randomized crossover trial in patients with episodic tension-type headache, applying a 10 percent peppermint oil solution in ethanol to the forehead and temples at headache onset. Topical peppermint oil reduced headache intensity equivalently to oral paracetamol (acetaminophen) 1 g over the 60 minutes following application, with both being significantly superior to placebo. The mechanism is consistent with TRPM8-mediated cutaneous cooling followed by sensory neuron desensitization reducing pain signaling in the trigeminal area.<ref name="gobel1996">Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type." Nervenarzt. 1996;67(8):672-681. PMID 8805113.</ref>

A 2016 confirmatory study from the same group reaffirmed the efficacy of topical peppermint oil for acute tension-type headache in a larger sample.<ref name="gobel2016">Gobel H, Heinze A, Heinze-Kuhn K, Gobel A, Gobel C. "[Peppermint oil in the acute treatment of tension-type headache]." Schmerz. 2016;30(3):295-310. PMID 27106030.</ref>

'''Functional dyspepsia'''

Peppermint oil in combination with caraway oil (Enteroplant; MCP Pharma, Germany) has been evaluated in several randomized trials for functional dyspepsia, showing significant improvement over placebo in epigastric pain, nausea, and bloating. The combination is included as a component of the multi-herb preparation Iberogast, which has its own clinical evidence base for functional dyspepsia.{{citation needed}}

| preparations = Infusion (tea): 3 to 4 g dried leaf per cup of hot water, covered while steeping (volatile oil retention). Drunk after meals for digestive complaints; as a steam inhalant for nasal congestion (pour into a bowl and inhale steam with a towel over the head). Note that peppermint tea is the preparation with the weakest IBS evidence; the enteric-coated capsule form is the evidence-based preparation for this indication.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation.

Enteric-coated peppermint oil capsules (Colpermin; Pepogest; Mintec; generic equivalents): the only form with robust IBS clinical trial evidence. Enteric coating is essential: the coating is designed to withstand gastric acid and dissolve at the more alkaline pH of the duodenum and small intestine, delivering the oil to the intestinal target rather than the stomach. These capsules must NOT be taken simultaneously with antacids, proton pump inhibitors, or H2 blockers that alkalinize the stomach -- premature dissolution of the enteric coat risks upper GI side effects. Standard commercial dose: 187 to 225 mg three times daily, taken before meals.

Essential oil (topical): 10 percent peppermint oil in ethanol or carrier oil, applied to forehead and temples for tension headache; 2 to 3 percent in carrier oil for massage of muscle ache or abdominal spasm; steam inhalant (2 to 3 drops in hot water) for nasal congestion. Do not apply neat oil to facial skin of children or to the face or chest of infants.

Mouthwash and confectionery: standardized products are not medicinal preparations but carry genuine antimicrobial and breath-freshening effects from the menthol content.

| dosing = '''Internal preparations'''

Infusion: 3 to 4 g dried leaf per cup, three to four times daily, ideally after meals. Cover the vessel while steeping; the volatile oil evaporates readily.

Tincture: 1 to 2 ml three times daily, diluted in water.

Enteric-coated peppermint oil capsules (for IBS): 187 to 225 mg three times daily, 30 to 60 minutes before meals. Do not crush or chew. Separate from antacid use by at least two hours. The full therapeutic effect in IBS develops over two to four weeks of regular use; do not assess as a failure after a single dose.

'''External preparations'''

Tension headache: 10 percent peppermint oil in ethanol, applied by cotton ball or rollerball applicator to forehead and both temples at headache onset; repeat at 15 and 30 minutes as needed. Keep well away from eyes. This is the protocol used in the Gobel trials.

Muscle tension and spasm: 2 to 3 percent essential oil in carrier oil, applied by massage to affected area.

Nasal congestion: 2 to 3 drops essential oil in a bowl of hot water; inhale steam for 5 to 10 minutes with a towel draped over head and bowl. Do not use this method with children under 12, or with infants under any circumstances.

'''Recreational dose ladder'''

Peppermint has no established recreational dose structure. Menthol's TRPM8-mediated cooling sensation is pleasurable and widely exploited in confectionery, oral hygiene, and tobacco products; however, the sensation is immediate, topical, and non-dose-escalating -- there is no psychoactive intensification with increasing dose, and no recreational culture of peppermint use as a psychoactive agent exists in any documented tradition. At high oral doses, menthol produces nausea and GI discomfort rather than pleasure; the pharmacological ceiling of the desirable effect is reached at modest concentrations. No dose ladder is warranted.

| pharmacokinetics = Menthol is rapidly absorbed from the gastrointestinal tract following oral ingestion of non-enteric-coated preparations; enteric-coated formulations delay absorption to the small intestine, which is the therapeutic intent for IBS. Menthol undergoes hepatic glucuronidation and sulfation; the conjugated metabolites are excreted renally, with menthol glucuronide detectable in urine as a biomarker of exposure. The elimination half-life of menthol is approximately one to two hours. Following topical application, menthol is absorbed dermally at a rate sufficient to produce detectable plasma concentrations; dermal absorption is faster with ethanol-based compared to oil-based vehicles.{{citation needed}}

| interactions = Antacids, proton pump inhibitors, H2 receptor antagonists: alkalinization of gastric pH by any of these agents can dissolve the enteric coating of peppermint oil capsules prematurely, causing upper GI side effects (heartburn, nausea, belching) and reducing delivery to the intended intestinal target. Antacids should be separated from enteric-coated capsule dosing by a minimum of two hours.

Central nervous system depressants: additive effects possible with sedating medicines and herbal preparations; peppermint has mild CNS-relaxing effects at therapeutic doses.

Cyclosporine: case reports suggest possible elevation of cyclosporine plasma levels in transplant recipients using peppermint oil preparations; a potential CYP3A4 interaction. Transplant patients on cyclosporine should not use peppermint oil preparations without specialist input.{{citation needed}}

Cyclosporine aside, cytochrome P450 inhibition by peppermint oil at standard enteric-coated capsule doses (187 to 225 mg three times daily) has not been documented as clinically significant in pharmacokinetic interaction studies.

| interactionsummary = Separate from antacids by 2 hours (enteric coat dissolution risk). Theoretical CYP3A4 interaction; case report of cyclosporine elevation. Additive CNS relaxant effect with sedatives.

| safety = The most important safety issue with peppermint is also the most preventable: administration to children under five, or inhalant menthol preparations applied near the face of infants. Menthol applied to the nose, mouth, or chest of infants and young children has caused laryngospasm and bronchospasm, including apnea, in case reports; this has occurred with direct application of peppermint oil or Vicks VapoRub-equivalent preparations to the chest or upper lip. Products containing menthol should not be applied near the face of children under five; for infants and toddlers, no menthol-containing preparations are appropriate.{{citation needed}}

Gastroesophageal reflux disease (GERD) and hiatal hernia: menthol relaxes the lower esophageal sphincter (LES). Peppermint tea and non-enteric-coated preparations should be avoided in patients with active reflux disease; enteric-coated capsules (which deliver the oil below the LES, to the intestine) are substantially lower-risk but should still be used with caution in severe or symptomatic GERD.

Pennyroyal (''Mentha'' pulegium) confusion: pennyroyal is a toxic mint-family plant sometimes sold as or confused with peppermint; its pulegone-rich essential oil has caused hepatic failure and maternal death when taken as an abortifacient. Any herb labeled as pennyroyal, European pennyroyal, or squaw mint should be treated as toxic. This warning applies to herbal suppliers and to patients who gather wild mints without botanical identification.

Gallstones: peppermint oil's choleretic effect stimulates the gallbladder; patients with known gallstones should use peppermint oil preparations cautiously, as stimulation of bile flow in the presence of obstructing stones could precipitate biliary colic.

Pregnancy: no clinical trial safety data; peppermint tea is used in traditional midwifery for pregnancy-related nausea and is generally considered safe at infusion doses; enteric-coated oil capsules at medicinal doses have not been evaluated in pregnancy and are not recommended.

| monitoring = No routine monitoring required for infusion use or enteric-coated capsules at standard IBS doses in otherwise healthy adults. Patients with GERD on enteric-coated capsules: symptom monitoring for worsening reflux. Transplant patients on cyclosporine: if using peppermint oil, check cyclosporine levels within two to four weeks of starting or changing dose.

| counseling = The formulation distinction is the most important thing to convey to patients using peppermint for IBS: only enteric-coated capsules have the clinical evidence base, because only they deliver the oil to the intestinal target. Peppermint tea, while pleasant and acceptable for mild general digestive symptoms, has not been tested for IBS and should not be substituted for the enteric-coated capsule in patients with established IBS diagnosis.

For tension headache, the topical preparation (10 percent peppermint oil in ethanol on forehead and temples) requires patient instruction on avoiding the eyes; a rollerball applicator is more practical than cotton-ball application for self-use. The effect onset is rapid -- patients should expect some relief within 15 to 30 minutes, earlier than with oral paracetamol.

Parents of infants and young children should be advised specifically that peppermint oil and all mentholated preparations should not be applied to the face, nose, or chest of children under five, and not at all to the face of infants.

| regulatory = '''Germany and European Union'''

German Commission E: peppermint oil approved for spastic complaints of the upper GI tract, bile duct and gallbladder; external use for myalgia and neuralgia; and inhalation for diseases of the upper respiratory tract. Peppermint leaf (dried herb) approved for carminative and antispasmodic use in the GI tract.

EMA: positive assessment issued for peppermint oil in enteric-coated capsules for IBS, classified as a well-established use (based on clinical trial evidence) rather than traditional use -- a stronger regulatory designation reflecting the Cochrane-level evidence base. This distinguishes peppermint oil from most other botanical preparations in the EMA monograph system.<ref name="ema-peppermint">European Union herbal monograph on Mentha x piperita L., aetheroleum. EMA/HMPC/522410/2013. Committee on Herbal Medicinal Products (HMPC). First published: 24 July 2020. https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum</ref>

'''United States'''

Peppermint oil: GRAS as a food flavoring. Sold as a dietary supplement under DSHEA without FDA evaluation for therapeutic claims. No FDA-approved therapeutic indication.

'''United Kingdom'''

Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lemon balm

MDElliottMD — Tue, 26 May 2026 18:56:07 GMT